Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Apr
19
Today In Oncology
Melanoma Can AI Enable Diagnosis Prediction
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo